What does this research mean for the field?

The failure of candidate therapies for cancer therapy-related cognitive impairment to translate into clinical practice is primarily driven by methodological gaps between preclinical models and human cancer survivorship, such as inadequate demographic modeling and mismatched endpoints. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To synthesize current candidate pharmacological and nonpharmacological therapies for cancer therapy-related cognitive impairment (CRCI) and evaluate the methodological barriers preventing preclinical success from translating into clinical efficacy.

September 14, 2026Pharmacological ReportsOpen Access

Cancer therapy-related cognitive impairment, part 2: from bench to bedside—and back: why candidate therapies for cancer therapy-related cognitive impairment fail to translate

View Full Paper

Ask AI

Bookmark

Authors

STSelene TertemizJagiellonian University JDJan DetkaJagiellonian University KSKinga SałatJagiellonian University

Discussion

Member takes

Implication

Review reveals methodological gaps hindering treatments for cancer therapy-related cognitive impairment, highlighting the need for oncologically safe, clinically predictive models.

Key Points

To synthesize current candidate pharmacological and nonpharmacological therapies for cancer therapy-related cognitive impairment (CRCI) and evaluate the methodological barriers preventing preclinical success from translating into clinical efficacy.
Critically reviewed the biological rationales, mechanisms of action, and preclinical versus clinical evidence for candidate CRCI interventions.
Evaluated translational discrepancies between preclinical animal models and human cancer survivorship, focusing on model fidelity, endpoint comparability, and drug interactions.
Identified critical preclinical limitations, including the routine use of non-tumor-bearing animals, neglect of age, sex, and hormonal context, misalignment of behavioral and clinical endpoints, and poorly matched biomarkers.
Highlighted the widespread failure to assess whether neuroprotective therapies inadvertently interfere with anticancer treatment efficacy.
Proposed a translational roadmap to design mechanism-informed, clinically aligned, and oncologically safe therapies for CRCI.

Cite This Study

Tertemiz et al. (2026) studied this question.

synapsesocial.com/papers/6aa7b29f0926e14a848b11ca https://doi.org/10.1007/s43440-026-00893-z

View Full Paper

Ask AI

Bookmark

Implication

Review reveals methodological gaps hindering treatments for cancer therapy-related cognitive impairment, highlighting the need for oncologically safe, clinically predictive models.

Cancer therapy-related cognitive impairment, part 2: from bench to bedside—and back: why candidate therapies for cancer therapy-related cognitive impairment fail to translate

Discussion

Member takes

Implication

Key Points

Cite This Study

Cancer therapy-related cognitive impairment, part 2: from bench to bedside—and back: why candidate therapies for cancer therapy-related cognitive impairment fail to translate

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider